全文获取类型
收费全文 | 539469篇 |
免费 | 35794篇 |
国内免费 | 849篇 |
专业分类
耳鼻咽喉 | 7258篇 |
儿科学 | 17431篇 |
妇产科学 | 14466篇 |
基础医学 | 88323篇 |
口腔科学 | 15040篇 |
临床医学 | 47180篇 |
内科学 | 98876篇 |
皮肤病学 | 12641篇 |
神经病学 | 37884篇 |
特种医学 | 19382篇 |
外国民族医学 | 63篇 |
外科学 | 80859篇 |
综合类 | 9130篇 |
现状与发展 | 2篇 |
一般理论 | 125篇 |
预防医学 | 40767篇 |
眼科学 | 12590篇 |
药学 | 42476篇 |
中国医学 | 1126篇 |
肿瘤学 | 30493篇 |
出版年
2018年 | 5600篇 |
2016年 | 4552篇 |
2015年 | 5158篇 |
2014年 | 6964篇 |
2013年 | 10782篇 |
2012年 | 14796篇 |
2011年 | 16216篇 |
2010年 | 9452篇 |
2009年 | 8718篇 |
2008年 | 15249篇 |
2007年 | 16349篇 |
2006年 | 16460篇 |
2005年 | 15863篇 |
2004年 | 15352篇 |
2003年 | 14556篇 |
2002年 | 14351篇 |
2001年 | 24823篇 |
2000年 | 25724篇 |
1999年 | 21114篇 |
1998年 | 5682篇 |
1997年 | 4891篇 |
1996年 | 5219篇 |
1995年 | 4776篇 |
1994年 | 4463篇 |
1992年 | 16038篇 |
1991年 | 16570篇 |
1990年 | 16673篇 |
1989年 | 16021篇 |
1988年 | 14766篇 |
1987年 | 14618篇 |
1986年 | 13777篇 |
1985年 | 13127篇 |
1984年 | 9764篇 |
1983年 | 8373篇 |
1982年 | 4636篇 |
1981年 | 4316篇 |
1979年 | 9522篇 |
1978年 | 6947篇 |
1977年 | 5852篇 |
1976年 | 5675篇 |
1975年 | 6464篇 |
1974年 | 7719篇 |
1973年 | 7189篇 |
1972年 | 7042篇 |
1971年 | 6752篇 |
1970年 | 6217篇 |
1969年 | 5933篇 |
1968年 | 5578篇 |
1967年 | 5033篇 |
1966年 | 4470篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
31.
R. Di Raimondo J. Sanz-Esporrn R. Pl I. Sanz-Martn F. Luengo F. Vignoletti J. Nuez Mariano Sanz 《Clinical oral investigations》2020,24(7):2351-2361
To evaluate the changes in alveolar contour after guided bone regeneration (GBR) with two different combinations of biomaterials in dehiscence defects arou 相似文献
32.
33.
34.
35.
36.
37.
Feasibility and Diagnostic Potential of Pulmonary Transit Time Measurement by Contrast Echocardiography: A Pilot Study
下载免费PDF全文
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
38.
E. M. Peterman C. Sullivan M. F. Goody I. Rodriguez-Nunez J. A. Yoder C. H. Kim 《Infection and immunity》2015,83(1):430-440
Mitochondria are known primarily as the location of the electron transport chain and energy production in cells. More recently, mitochondria have been shown to be signaling centers for apoptosis and inflammation. Reactive oxygen species (ROS) generated as by-products of the electron transport chain within mitochondria significantly impact cellular signaling pathways. Because of the toxic nature of ROS, mitochondria possess an antioxidant enzyme, superoxide dismutase 2 (SOD2), to neutralize ROS. If mitochondrial antioxidant enzymes are overwhelmed during severe infections, mitochondrial dysfunction can occur and lead to multiorgan failure or death. Pseudomonas aeruginosa is an opportunistic pathogen that can infect immunocompromised patients. Infochemicals and exotoxins associated with P. aeruginosa are capable of causing mitochondrial dysfunction. In this work, we describe the roles of SOD2 and mitochondrial ROS regulation in the zebrafish innate immune response to P. aeruginosa infection. sod2 is upregulated in mammalian macrophages and neutrophils in response to lipopolysaccharide in vitro, and sod2 knockdown in zebrafish results in an increased bacterial burden. Further investigation revealed that phagocyte numbers are compromised in Sod2-deficient zebrafish. Addition of the mitochondrion-targeted ROS-scavenging chemical MitoTEMPO rescues neutrophil numbers and reduces the bacterial burden in Sod2-deficient zebrafish. Our work highlights the importance of mitochondrial ROS regulation by SOD2 in the context of innate immunity and supports the use of mitochondrion-targeted ROS scavengers as potential adjuvant therapies during severe infections. 相似文献
39.
40.
Chih-Wei Hsu Sheng-Yu Lee Yao-Hsu Yang Liang-Jen Wang 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(10):653
BackgroundGeneric antidepressants are approved on the market based on evidence of bioequivalence to their brand-name versions. We aimed to assess whether generic antidepressants exert equal effectiveness as their brand-name counterparts for treating patients with depressive disorders.MethodsIn a nationwide, population-based cohort in Taiwan from 1997 through 2013, patients with a diagnosis of a depressive disorder aged between 18 and 65 years who were new users of antidepressant drugs were classified into either the brand-name group or the generic group. All patients were followed up until medication discontinuation or the end of the study period. We assessed the risk for hospitalization as a primary outcome and augmentation therapy, daily dose, medication discontinuation, or switching to another antidepressant as secondary outcomes.ResultsA total of 277 651 brand-name users (35.8% male; mean age: 41.2 years) and 270 583 generic users (35.8% male; mean age: 41.0 years) were divided into 10 different antidepressant groups (fluoxetine, sertraline, paroxetine, escitalopram, citalopram, venlafaxine, mirtazapine, moclobemide, imipramine, and bupropion). We found that patients treated with the generic form of sertraline, paroxetine, escitalopram, venlafaxine, mirtazapine, and bupropion demonstrated significantly higher risks of psychiatric hospitalization (adjusted hazard ratios ranged from 1.20–2.34), compared to their brand-name counterparts. The differences between brand-name antidepressants and their generic counterparts in secondary outcomes varied across different drugs.ConclusionsCompared to most generic antidepressants, brand-name drugs exhibited more protective effects on psychiatric hospitalization for depressive patients. These findings could serve as an important reference for clinicians when encountering patients with depressive disorder. 相似文献